ClinicalTrials.gov record
Completed Early Phase 1 Interventional

Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer

ClinicalTrials.gov ID: NCT01821612

Public ClinicalTrials.gov record NCT01821612. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 2:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Neoadjuvant FOLFIRINOX and Chemoradiation Followed by Definitive Surgery and Postoperative Gemcitabine for Patients with Borderline Resectable Pancreatic Adenocarcinoma: an Intergroup Single-Arm Pilot Study

Study identification

NCT ID
NCT01821612
Recruitment status
Completed
Study type
Interventional
Phase
Early Phase 1
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Enrollment
23 participants

Conditions and interventions

Interventions

  • 5-fluorouracil Drug
  • capecitabine Drug
  • gemcitabine Drug
  • irinotecan Drug
  • leucovorin Drug
  • oxaliplatin Drug
  • radiation Radiation
  • surgery Procedure

Drug · Radiation · Procedure

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 28, 2013
Primary completion
Oct 31, 2014
Completion
Jun 14, 2018
Last update posted
Jan 12, 2025

2013 – 2018

United States locations

U.S. sites
14
U.S. states
11
U.S. cities
14
Facility City State ZIP Site status
UC San Diego Moores Cancer Center La Jolla California 92093
University of Chicago Comprehensive Cancer Center Chicago Illinois 60637
NorthShore University HealthSystem-Evanston Hospital Evanston Illinois 60201
The James Graham Brown Cancer Center at University of Louisville Louisville Kentucky 40202
Ochsner Medical Center Jefferson New Orleans Louisiana 70121
Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore Maryland 21287
Mayo Clinic Rochester Minnesota 55905
Wake Forest University Health Sciences Winston-Salem North Carolina 27157
University of Cincinnati Cincinnati Ohio 45267
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210
University Pointe West Chester Ohio 45069
Fox Chase Cancer Center Philadelphia Pennsylvania 19111
M D Anderson Cancer Center Houston Texas 77030
University of Wisconsin Hospital and Clinics Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01821612, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 12, 2025 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01821612 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →